Topics

Incyte pays MorphoSys $750M upfront in lymphoma drug partnership

15:16 EST 14 Jan 2020 | MedCity News

The deal, worth up to $2B in milestones and other other payments, involves the monoclonal antibody tafasitamab, for which MorphoSys recently submitted an FDA approval application.

Original Article: Incyte pays MorphoSys $750M upfront in lymphoma drug partnership

NEXT ARTICLE

More From BioPortfolio on "Incyte pays MorphoSys $750M upfront in lymphoma drug partnership"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...